Gmt Capital Corp Cassava Sciences Inc Transaction History
Gmt Capital Corp
- $2.21 Billion
- Q3 2025
A detailed history of Gmt Capital Corp transactions in Cassava Sciences Inc stock. As of the latest transaction made, Gmt Capital Corp holds 450,100 shares of SAVA stock, worth $1.24 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
450,100
Previous 450,100
-0.0%
Holding current value
$1.24 Million
Previous $814,000
60.81%
% of portfolio
0.06%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
132Shares Held
15.9MCall Options Held
1.26MPut Options Held
791K-
Black Rock Inc. New York, NY3.22MShares$8.89 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.29MShares$6.32 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.06MShares$5.69 Million0.01% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny962KShares$2.65 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY565KShares$1.56 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $111M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...